nodes	percent_of_prediction	percent_of_DWPC	metapath
Diclofenac—CYP2E1—Methimazole—Graves' disease	0.189	0.249	CbGbCtD
Diclofenac—CYP2B6—Methimazole—Graves' disease	0.186	0.246	CbGbCtD
Diclofenac—CYP2C19—Methimazole—Graves' disease	0.118	0.156	CbGbCtD
Diclofenac—CYP1A2—Methimazole—Graves' disease	0.109	0.144	CbGbCtD
Diclofenac—CYP2C9—Methimazole—Graves' disease	0.0984	0.13	CbGbCtD
Diclofenac—CYP3A4—Methimazole—Graves' disease	0.0572	0.0755	CbGbCtD
Diclofenac—CXCR1—adipose tissue—Graves' disease	0.0072	0.0922	CbGeAlD
Diclofenac—Neuritis—Methimazole—Graves' disease	0.00626	0.0499	CcSEcCtD
Diclofenac—Neuritis—Propylthiouracil—Graves' disease	0.00533	0.0425	CcSEcCtD
Diclofenac—Skin ulcer—Propylthiouracil—Graves' disease	0.00511	0.0407	CcSEcCtD
Diclofenac—Aplastic anaemia—Methimazole—Graves' disease	0.00439	0.035	CcSEcCtD
Diclofenac—ASIC1—adipose tissue—Graves' disease	0.00428	0.0548	CbGeAlD
Diclofenac—KCNQ2—eye—Graves' disease	0.00424	0.0543	CbGeAlD
Diclofenac—Vasculitis—Propylthiouracil—Graves' disease	0.00407	0.0325	CcSEcCtD
Diclofenac—Lymphadenopathy—Methimazole—Graves' disease	0.00398	0.0317	CcSEcCtD
Diclofenac—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00373	0.0298	CcSEcCtD
Diclofenac—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00338	0.027	CcSEcCtD
Diclofenac—PLA2G2A—connective tissue—Graves' disease	0.00336	0.0431	CbGeAlD
Diclofenac—Hepatic failure—Propylthiouracil—Graves' disease	0.00321	0.0256	CcSEcCtD
Diclofenac—KCNQ2—pituitary gland—Graves' disease	0.00315	0.0403	CbGeAlD
Diclofenac—Renal failure acute—Propylthiouracil—Graves' disease	0.00313	0.0249	CcSEcCtD
Diclofenac—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00306	0.0244	CcSEcCtD
Diclofenac—TTR—eye—Graves' disease	0.00263	0.0337	CbGeAlD
Diclofenac—Drowsiness—Methimazole—Graves' disease	0.00262	0.0209	CcSEcCtD
Diclofenac—PLA2G2A—pituitary gland—Graves' disease	0.00259	0.0332	CbGeAlD
Diclofenac—PLA2G2A—adipose tissue—Graves' disease	0.00258	0.033	CbGeAlD
Diclofenac—CXCL8—pituitary gland—Graves' disease	0.00256	0.0328	CbGeAlD
Diclofenac—Neuropathy peripheral—Methimazole—Graves' disease	0.00256	0.0204	CcSEcCtD
Diclofenac—CXCL8—adipose tissue—Graves' disease	0.00255	0.0327	CbGeAlD
Diclofenac—Jaundice—Methimazole—Graves' disease	0.00255	0.0203	CcSEcCtD
Diclofenac—TTR—connective tissue—Graves' disease	0.00254	0.0325	CbGeAlD
Diclofenac—Agranulocytosis—Methimazole—Graves' disease	0.00244	0.0195	CcSEcCtD
Diclofenac—Hepatitis—Methimazole—Graves' disease	0.00235	0.0187	CcSEcCtD
Diclofenac—ALOX5—connective tissue—Graves' disease	0.0023	0.0295	CbGeAlD
Diclofenac—CXCR1—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00228	0.0596	CbGpPWpGaD
Diclofenac—PLA2G2A—thyroid gland—Graves' disease	0.00223	0.0286	CbGeAlD
Diclofenac—Drowsiness—Propylthiouracil—Graves' disease	0.00222	0.0177	CcSEcCtD
Diclofenac—SLCO1C1—pituitary gland—Graves' disease	0.00219	0.028	CbGeAlD
Diclofenac—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00218	0.0174	CcSEcCtD
Diclofenac—SLCO1C1—adipose tissue—Graves' disease	0.00218	0.0279	CbGeAlD
Diclofenac—Jaundice—Propylthiouracil—Graves' disease	0.00217	0.0173	CcSEcCtD
Diclofenac—Agranulocytosis—Propylthiouracil—Graves' disease	0.00208	0.0165	CcSEcCtD
Diclofenac—Alopecia—Methimazole—Graves' disease	0.00208	0.0165	CcSEcCtD
Diclofenac—SCN4A—pituitary gland—Graves' disease	0.00201	0.0258	CbGeAlD
Diclofenac—Haemoglobin—Propylthiouracil—Graves' disease	0.00201	0.016	CcSEcCtD
Diclofenac—SCN4A—adipose tissue—Graves' disease	0.002	0.0256	CbGeAlD
Diclofenac—Hepatitis—Propylthiouracil—Graves' disease	0.002	0.0159	CcSEcCtD
Diclofenac—Haemorrhage—Propylthiouracil—Graves' disease	0.002	0.0159	CcSEcCtD
Diclofenac—TTR—pituitary gland—Graves' disease	0.00196	0.0251	CbGeAlD
Diclofenac—SLCO1C1—thyroid gland—Graves' disease	0.00189	0.0242	CbGeAlD
Diclofenac—ASIC1—Ion channel transport—GABRA3—Graves' disease	0.00187	0.0489	CbGpPWpGaD
Diclofenac—Vertigo—Methimazole—Graves' disease	0.00184	0.0146	CcSEcCtD
Diclofenac—Leukopenia—Methimazole—Graves' disease	0.00183	0.0146	CcSEcCtD
Diclofenac—ALOX5—adipose tissue—Graves' disease	0.00176	0.0226	CbGeAlD
Diclofenac—Alopecia—Propylthiouracil—Graves' disease	0.00176	0.0141	CcSEcCtD
Diclofenac—Myalgia—Methimazole—Graves' disease	0.00174	0.0139	CcSEcCtD
Diclofenac—Arthralgia—Methimazole—Graves' disease	0.00174	0.0139	CcSEcCtD
Diclofenac—SCN4A—thyroid gland—Graves' disease	0.00173	0.0222	CbGeAlD
Diclofenac—Dysgeusia—Propylthiouracil—Graves' disease	0.0017	0.0136	CcSEcCtD
Diclofenac—TTR—thyroid gland—Graves' disease	0.00169	0.0216	CbGeAlD
Diclofenac—Oedema—Methimazole—Graves' disease	0.00167	0.0133	CcSEcCtD
Diclofenac—Thrombocytopenia—Methimazole—Graves' disease	0.00163	0.013	CcSEcCtD
Diclofenac—SLC22A8—eye—Graves' disease	0.00161	0.0207	CbGeAlD
Diclofenac—Vertigo—Propylthiouracil—Graves' disease	0.00156	0.0124	CcSEcCtD
Diclofenac—Leukopenia—Propylthiouracil—Graves' disease	0.00156	0.0124	CcSEcCtD
Diclofenac—ALOX5—thyroid gland—Graves' disease	0.00153	0.0196	CbGeAlD
Diclofenac—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00152	0.0121	CcSEcCtD
Diclofenac—Paraesthesia—Methimazole—Graves' disease	0.0015	0.0119	CcSEcCtD
Diclofenac—Somnolence—Methimazole—Graves' disease	0.00148	0.0118	CcSEcCtD
Diclofenac—Arthralgia—Propylthiouracil—Graves' disease	0.00148	0.0118	CcSEcCtD
Diclofenac—Myalgia—Propylthiouracil—Graves' disease	0.00148	0.0118	CcSEcCtD
Diclofenac—Dyspepsia—Methimazole—Graves' disease	0.00147	0.0117	CcSEcCtD
Diclofenac—Oedema—Propylthiouracil—Graves' disease	0.00142	0.0113	CcSEcCtD
Diclofenac—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00139	0.0111	CcSEcCtD
Diclofenac—Urticaria—Methimazole—Graves' disease	0.00133	0.0106	CcSEcCtD
Diclofenac—Body temperature increased—Methimazole—Graves' disease	0.00132	0.0105	CcSEcCtD
Diclofenac—CXCR1—Peptide GPCRs—TSHR—Graves' disease	0.00131	0.0344	CbGpPWpGaD
Diclofenac—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00129	0.0103	CcSEcCtD
Diclofenac—Paraesthesia—Propylthiouracil—Graves' disease	0.00127	0.0102	CcSEcCtD
Diclofenac—Somnolence—Propylthiouracil—Graves' disease	0.00126	0.0101	CcSEcCtD
Diclofenac—Dyspepsia—Propylthiouracil—Graves' disease	0.00125	0.00995	CcSEcCtD
Diclofenac—ABCC4—adipose tissue—Graves' disease	0.0012	0.0154	CbGeAlD
Diclofenac—Pruritus—Methimazole—Graves' disease	0.00118	0.00941	CcSEcCtD
Diclofenac—Urticaria—Propylthiouracil—Graves' disease	0.00113	0.00898	CcSEcCtD
Diclofenac—Body temperature increased—Propylthiouracil—Graves' disease	0.00112	0.00894	CcSEcCtD
Diclofenac—CXCR1—Chemokine receptors bind chemokines—CXCL10—Graves' disease	0.00106	0.0278	CbGpPWpGaD
Diclofenac—Vomiting—Methimazole—Graves' disease	0.00106	0.00846	CcSEcCtD
Diclofenac—Rash—Methimazole—Graves' disease	0.00105	0.00839	CcSEcCtD
Diclofenac—Dermatitis—Methimazole—Graves' disease	0.00105	0.00838	CcSEcCtD
Diclofenac—Headache—Methimazole—Graves' disease	0.00105	0.00833	CcSEcCtD
Diclofenac—ABCC4—thyroid gland—Graves' disease	0.00104	0.0133	CbGeAlD
Diclofenac—ABCC1—pituitary gland—Graves' disease	0.00103	0.0132	CbGeAlD
Diclofenac—ABCC1—adipose tissue—Graves' disease	0.00103	0.0131	CbGeAlD
Diclofenac—Pruritus—Propylthiouracil—Graves' disease	0.001	0.008	CcSEcCtD
Diclofenac—Nausea—Methimazole—Graves' disease	0.000991	0.0079	CcSEcCtD
Diclofenac—PTGS1—connective tissue—Graves' disease	0.000923	0.0118	CbGeAlD
Diclofenac—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SCGB3A2—Graves' disease	0.000911	0.0239	CbGpPWpGaD
Diclofenac—Vomiting—Propylthiouracil—Graves' disease	0.000902	0.00719	CcSEcCtD
Diclofenac—Rash—Propylthiouracil—Graves' disease	0.000894	0.00713	CcSEcCtD
Diclofenac—Dermatitis—Propylthiouracil—Graves' disease	0.000894	0.00712	CcSEcCtD
Diclofenac—Headache—Propylthiouracil—Graves' disease	0.000889	0.00708	CcSEcCtD
Diclofenac—ABCC1—thyroid gland—Graves' disease	0.000888	0.0114	CbGeAlD
Diclofenac—PTGS2—connective tissue—Graves' disease	0.000883	0.0113	CbGeAlD
Diclofenac—CYP2C8—pituitary gland—Graves' disease	0.000877	0.0112	CbGeAlD
Diclofenac—Nausea—Propylthiouracil—Graves' disease	0.000843	0.00672	CcSEcCtD
Diclofenac—CYP1A1—adipose tissue—Graves' disease	0.000806	0.0103	CbGeAlD
Diclofenac—PTGS1—pituitary gland—Graves' disease	0.000711	0.00911	CbGeAlD
Diclofenac—PTGS1—adipose tissue—Graves' disease	0.000708	0.00907	CbGeAlD
Diclofenac—CYP1A2—thyroid gland—Graves' disease	0.000708	0.00906	CbGeAlD
Diclofenac—CYP1A1—thyroid gland—Graves' disease	0.000698	0.00894	CbGeAlD
Diclofenac—PTGS2—pituitary gland—Graves' disease	0.00068	0.00871	CbGeAlD
Diclofenac—PTGS2—adipose tissue—Graves' disease	0.000677	0.00867	CbGeAlD
Diclofenac—ASIC1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000651	0.017	CbGpPWpGaD
Diclofenac—CYP2E1—thyroid gland—Graves' disease	0.000637	0.00815	CbGeAlD
Diclofenac—PTGS1—thyroid gland—Graves' disease	0.000613	0.00785	CbGeAlD
Diclofenac—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.000579	0.0151	CbGpPWpGaD
Diclofenac—KCNQ2—Neuronal System—GABRA3—Graves' disease	0.000556	0.0145	CbGpPWpGaD
Diclofenac—KCNQ3—Neuronal System—GABRA3—Graves' disease	0.000556	0.0145	CbGpPWpGaD
Diclofenac—CXCL8—Chemokine receptors bind chemokines—CXCL10—Graves' disease	0.000479	0.0125	CbGpPWpGaD
Diclofenac—PLA2G2A—Spinal Cord Injury—CXCL10—Graves' disease	0.000458	0.012	CbGpPWpGaD
Diclofenac—CXCL8—TSLP Signaling Pathway—IL2RA—Graves' disease	0.000421	0.011	CbGpPWpGaD
Diclofenac—ABCB1—pituitary gland—Graves' disease	0.000421	0.00539	CbGeAlD
Diclofenac—ABCB1—adipose tissue—Graves' disease	0.000419	0.00537	CbGeAlD
Diclofenac—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000418	0.0109	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—HLA-E—Graves' disease	0.000417	0.0109	CbGpPWpGaD
Diclofenac—CXCR1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000415	0.0109	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—CD40—Graves' disease	0.000407	0.0107	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—CTLA4—Graves' disease	0.000401	0.0105	CbGpPWpGaD
Diclofenac—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000401	0.0105	CbGpPWpGaD
Diclofenac—CXCR1—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.0004	0.0105	CbGpPWpGaD
Diclofenac—CXCL8—Overview of nanoparticle effects—TNF—Graves' disease	0.000371	0.00972	CbGpPWpGaD
Diclofenac—ABCB1—thyroid gland—Graves' disease	0.000363	0.00464	CbGeAlD
Diclofenac—CXCR1—G alpha (i) signalling events—CXCL10—Graves' disease	0.000337	0.00882	CbGpPWpGaD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—CD40—Graves' disease	0.000332	0.00869	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—HLA-DQB1—Graves' disease	0.00033	0.00865	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00032	0.00839	CbGpPWpGaD
Diclofenac—CXCL8—EBV LMP1 signaling—TNF—Graves' disease	0.000319	0.00834	CbGpPWpGaD
Diclofenac—CXCR1—GPCR ligand binding—TSHR—Graves' disease	0.000316	0.00827	CbGpPWpGaD
Diclofenac—PLA2G2A—Spinal Cord Injury—ICAM1—Graves' disease	0.000303	0.00794	CbGpPWpGaD
Diclofenac—CXCL8—AP-1 transcription factor network—HLA-A—Graves' disease	0.000303	0.00793	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—HLA-B—Graves' disease	0.000297	0.00777	CbGpPWpGaD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—CXCL10—Graves' disease	0.000297	0.00776	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—FASLG—Graves' disease	0.00029	0.00759	CbGpPWpGaD
Diclofenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—Graves' disease	0.000283	0.00742	CbGpPWpGaD
Diclofenac—ALOX5—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000282	0.00737	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—FAS—Graves' disease	0.00028	0.00732	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—IL2RA—Graves' disease	0.000278	0.00728	CbGpPWpGaD
Diclofenac—PLA2G2A—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000275	0.0072	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—HLA-A—Graves' disease	0.000275	0.0072	CbGpPWpGaD
Diclofenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—Graves' disease	0.000272	0.00711	CbGpPWpGaD
Diclofenac—CXCR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000268	0.00702	CbGpPWpGaD
Diclofenac—SLCO1C1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000266	0.00697	CbGpPWpGaD
Diclofenac—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000265	0.00693	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—CXCL10—Graves' disease	0.000264	0.00691	CbGpPWpGaD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.000259	0.00678	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.000253	0.00663	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—HLA-DRB1—Graves' disease	0.000251	0.00658	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000235	0.00616	CbGpPWpGaD
Diclofenac—CXCL8—Glucocorticoid receptor regulatory network—ICAM1—Graves' disease	0.000234	0.00613	CbGpPWpGaD
Diclofenac—CXCL8—ATF-2 transcription factor network—IFNG—Graves' disease	0.000232	0.00607	CbGpPWpGaD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000232	0.00606	CbGpPWpGaD
Diclofenac—PLA2G2A—Spinal Cord Injury—IFNG—Graves' disease	0.000231	0.00604	CbGpPWpGaD
Diclofenac—ALOX5—Selenium Micronutrient Network—IFNG—Graves' disease	0.000214	0.00561	CbGpPWpGaD
Diclofenac—PLA2G2A—Spinal Cord Injury—IL1B—Graves' disease	0.000206	0.00539	CbGpPWpGaD
Diclofenac—PTGS1—Overview of nanoparticle effects—TNF—Graves' disease	0.000205	0.00536	CbGpPWpGaD
Diclofenac—CXCR1—GPCR ligand binding—CXCL10—Graves' disease	0.000204	0.00534	CbGpPWpGaD
Diclofenac—CXCL8—AP-1 transcription factor network—IFNG—Graves' disease	0.000202	0.00529	CbGpPWpGaD
Diclofenac—PLA2G2A—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000196	0.00513	CbGpPWpGaD
Diclofenac—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000191	0.00501	CbGpPWpGaD
Diclofenac—ALOX5—Selenium Micronutrient Network—IL1B—Graves' disease	0.000191	0.005	CbGpPWpGaD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000187	0.0049	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—IFNG—Graves' disease	0.000184	0.0048	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000183	0.0048	CbGpPWpGaD
Diclofenac—CXCL8—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.00018	0.00472	CbGpPWpGaD
Diclofenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.000179	0.00469	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—TSHR—Graves' disease	0.000178	0.00467	CbGpPWpGaD
Diclofenac—CXCL8—Glucocorticoid receptor regulatory network—IFNG—Graves' disease	0.000178	0.00466	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000176	0.0046	CbGpPWpGaD
Diclofenac—SLC22A11—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000175	0.00458	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—ICAM1—Graves' disease	0.000175	0.00458	CbGpPWpGaD
Diclofenac—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000171	0.00448	CbGpPWpGaD
Diclofenac—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000171	0.00447	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—IL1B—Graves' disease	0.000164	0.00428	CbGpPWpGaD
Diclofenac—PTGS2—Overview of nanoparticle effects—TNF—Graves' disease	0.000163	0.00426	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—TSHR—Graves' disease	0.000162	0.00424	CbGpPWpGaD
Diclofenac—CXCL8—G alpha (i) signalling events—CXCL10—Graves' disease	0.000152	0.00398	CbGpPWpGaD
Diclofenac—PLA2G2A—Spinal Cord Injury—TNF—Graves' disease	0.000149	0.00391	CbGpPWpGaD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—IFNG—Graves' disease	0.000146	0.00383	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—GC—Graves' disease	0.000143	0.00373	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—TSHR—Graves' disease	0.000143	0.00373	CbGpPWpGaD
Diclofenac—ALOX5—Selenium Micronutrient Network—TNF—Graves' disease	0.000139	0.00363	CbGpPWpGaD
Diclofenac—TTR—Extracellular matrix organization—ICAM1—Graves' disease	0.000137	0.00358	CbGpPWpGaD
Diclofenac—SLC22A8—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000133	0.00349	CbGpPWpGaD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000133	0.00349	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—IFNG—Graves' disease	0.000133	0.00348	CbGpPWpGaD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—IL1B—Graves' disease	0.00013	0.00341	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000129	0.00339	CbGpPWpGaD
Diclofenac—ABCC4—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000128	0.00335	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000126	0.00331	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000125	0.00326	CbGpPWpGaD
Diclofenac—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000124	0.00324	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000122	0.0032	CbGpPWpGaD
Diclofenac—ALB—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.000121	0.00317	CbGpPWpGaD
Diclofenac—CXCL8—Metabolism of proteins—B3GNT2—Graves' disease	0.000121	0.00317	CbGpPWpGaD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000121	0.00317	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000121	0.00316	CbGpPWpGaD
Diclofenac—CXCL8—Allograft Rejection—TNF—Graves' disease	0.000119	0.00311	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—IL1B—Graves' disease	0.000119	0.00311	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000116	0.00303	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—CXCL10—Graves' disease	0.000116	0.00303	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—CXCL10—Graves' disease	0.000115	0.00302	CbGpPWpGaD
Diclofenac—SLC22A6—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000111	0.00292	CbGpPWpGaD
Diclofenac—TTR—Disease—B3GNT2—Graves' disease	0.000111	0.00291	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.00011	0.00288	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—B3GNT2—Graves' disease	0.000108	0.00283	CbGpPWpGaD
Diclofenac—ABCC1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000107	0.00279	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—CXCL10—Graves' disease	0.000105	0.00274	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—GC—Graves' disease	0.000105	0.00274	CbGpPWpGaD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000104	0.00273	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000103	0.00269	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000102	0.00267	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—ICAM1—Graves' disease	9.87e-05	0.00258	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	9.81e-05	0.00257	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—ICAM1—Graves' disease	9.69e-05	0.00254	CbGpPWpGaD
Diclofenac—CXCL8—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	9.68e-05	0.00253	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—TSHR—Graves' disease	9.58e-05	0.00251	CbGpPWpGaD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	9.57e-05	0.0025	CbGpPWpGaD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—IL1B—Graves' disease	9.5e-05	0.00249	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	9.29e-05	0.00243	CbGpPWpGaD
Diclofenac—ALB—Vitamin B12 Metabolism—IFNG—Graves' disease	9.23e-05	0.00242	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—HLA-B—Graves' disease	9.22e-05	0.00241	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—CXCL10—Graves' disease	9.21e-05	0.00241	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—FASLG—Graves' disease	9.01e-05	0.00236	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—IL2RA—Graves' disease	8.82e-05	0.00231	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—FAS—Graves' disease	8.69e-05	0.00227	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—IL2RA—Graves' disease	8.64e-05	0.00226	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—TNF—Graves' disease	8.62e-05	0.00226	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—HLA-A—Graves' disease	8.54e-05	0.00224	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	8.29e-05	0.00217	CbGpPWpGaD
Diclofenac—ALB—Vitamin B12 Metabolism—IL1B—Graves' disease	8.23e-05	0.00215	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—GC—Graves' disease	8.1e-05	0.00212	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—TSHR—Graves' disease	8.06e-05	0.00211	CbGpPWpGaD
Diclofenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	8.02e-05	0.0021	CbGpPWpGaD
Diclofenac—CXCR1—Signaling by GPCR—IL2RA—Graves' disease	8.01e-05	0.0021	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—B3GNT2—Graves' disease	7.94e-05	0.00208	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—ICAM1—Graves' disease	7.84e-05	0.00205	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	7.8e-05	0.00204	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—ICAM1—Graves' disease	7.66e-05	0.00201	CbGpPWpGaD
Diclofenac—CXCL8—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	7.56e-05	0.00198	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—IFNG—Graves' disease	7.51e-05	0.00197	CbGpPWpGaD
Diclofenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	7.5e-05	0.00196	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—CD4—Graves' disease	7.39e-05	0.00193	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—IFNG—Graves' disease	7.37e-05	0.00193	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—TSHR—Graves' disease	7.32e-05	0.00191	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	7.18e-05	0.00188	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	7.12e-05	0.00186	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	7.12e-05	0.00186	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—GC—Graves' disease	7.05e-05	0.00184	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	7.01e-05	0.00184	CbGpPWpGaD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—TNF—Graves' disease	6.89e-05	0.0018	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—GC—Graves' disease	6.86e-05	0.00179	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—IL1B—Graves' disease	6.7e-05	0.00175	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.59e-05	0.00172	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—IL1B—Graves' disease	6.58e-05	0.00172	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.55e-05	0.00171	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—TSHR—Graves' disease	6.44e-05	0.00169	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	6.27e-05	0.00164	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	6.25e-05	0.00164	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CXCL10—Graves' disease	6.19e-05	0.00162	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	6.05e-05	0.00158	CbGpPWpGaD
Diclofenac—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	6.01e-05	0.00157	CbGpPWpGaD
Diclofenac—ALB—Vitamin B12 Metabolism—TNF—Graves' disease	5.97e-05	0.00156	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—IFNG—Graves' disease	5.97e-05	0.00156	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.88e-05	0.00154	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IFNG—Graves' disease	5.83e-05	0.00153	CbGpPWpGaD
Diclofenac—ALB—Transmembrane transport of small molecules—GABRA3—Graves' disease	5.79e-05	0.00152	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—IFNG—Graves' disease	5.7e-05	0.00149	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—GC—Graves' disease	5.57e-05	0.00146	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—GC—Graves' disease	5.37e-05	0.00141	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.36e-05	0.0014	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—B3GNT2—Graves' disease	5.34e-05	0.0014	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—IL1B—Graves' disease	5.32e-05	0.00139	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—CXCL10—Graves' disease	5.21e-05	0.00136	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—IL1B—Graves' disease	5.2e-05	0.00136	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—B3GNT2—Graves' disease	5.2e-05	0.00136	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—IL1B—Graves' disease	5.08e-05	0.00133	CbGpPWpGaD
Diclofenac—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	5.07e-05	0.00133	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—TNF—Graves' disease	5.01e-05	0.00131	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—TNF—Graves' disease	5.01e-05	0.00131	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—IL2RA—Graves' disease	4.93e-05	0.00129	CbGpPWpGaD
Diclofenac—ABCC1—Disease—B3GNT2—Graves' disease	4.86e-05	0.00127	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—TNF—Graves' disease	4.86e-05	0.00127	CbGpPWpGaD
Diclofenac—PTGS2—Selenium Micronutrient Network—TNF—Graves' disease	4.77e-05	0.00125	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—IL2RA—Graves' disease	4.73e-05	0.00124	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CXCL10—Graves' disease	4.73e-05	0.00124	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	4.58e-05	0.0012	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—GC—Graves' disease	4.54e-05	0.00119	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	4.54e-05	0.00119	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	4.54e-05	0.00119	CbGpPWpGaD
Diclofenac—TTR—Disease—HLA-A—Graves' disease	4.49e-05	0.00118	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	4.45e-05	0.00116	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	4.33e-05	0.00113	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—TSHR—Graves' disease	4.32e-05	0.00113	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	4.29e-05	0.00112	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—B3GNT2—Graves' disease	4.22e-05	0.00111	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CXCL10—Graves' disease	4.16e-05	0.00109	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—B3GNT2—Graves' disease	4.07e-05	0.00107	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—IL2RA—Graves' disease	3.98e-05	0.00104	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—TNF—Graves' disease	3.86e-05	0.00101	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—TNF—Graves' disease	3.8e-05	0.000994	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—TNF—Graves' disease	3.77e-05	0.000988	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—TNF—Graves' disease	3.69e-05	0.000965	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—IL2RA—Graves' disease	3.61e-05	0.000946	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—GC—Graves' disease	3.61e-05	0.000944	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—GC—Graves' disease	3.46e-05	0.000907	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—B3GNT2—Graves' disease	3.44e-05	0.000901	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—GC—Graves' disease	3.39e-05	0.000888	CbGpPWpGaD
Diclofenac—PTGS2—Disease—B3GNT2—Graves' disease	3.26e-05	0.000854	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—GC—Graves' disease	3.2e-05	0.000838	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—IL2RA—Graves' disease	3.18e-05	0.000833	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—GC—Graves' disease	2.93e-05	0.000768	CbGpPWpGaD
Diclofenac—ALB—Metabolism—GC—Graves' disease	2.92e-05	0.000763	CbGpPWpGaD
Diclofenac—TTR—Disease—CD4—Graves' disease	2.9e-05	0.000758	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CXCL10—Graves' disease	2.79e-05	0.000731	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—B3GNT2—Graves' disease	2.73e-05	0.000715	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—B3GNT2—Graves' disease	2.63e-05	0.000687	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—GC—Graves' disease	2.62e-05	0.000685	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—B3GNT2—Graves' disease	2.57e-05	0.000673	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.57e-05	0.000672	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—GC—Graves' disease	2.56e-05	0.000669	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—B3GNT2—Graves' disease	2.42e-05	0.000635	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—GC—Graves' disease	2.39e-05	0.000625	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—IL2RA—Graves' disease	2.23e-05	0.000584	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—B3GNT2—Graves' disease	2.22e-05	0.000582	CbGpPWpGaD
Diclofenac—ALB—Metabolism—B3GNT2—Graves' disease	2.21e-05	0.000579	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—IL2RA—Graves' disease	2.13e-05	0.000559	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—GC—Graves' disease	2.04e-05	0.000534	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—B3GNT2—Graves' disease	1.98e-05	0.000519	CbGpPWpGaD
Diclofenac—ABCC1—Disease—HLA-A—Graves' disease	1.97e-05	0.000515	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—B3GNT2—Graves' disease	1.94e-05	0.000507	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.82e-05	0.000476	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—B3GNT2—Graves' disease	1.81e-05	0.000474	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—GC—Graves' disease	1.57e-05	0.000412	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—B3GNT2—Graves' disease	1.55e-05	0.000405	CbGpPWpGaD
Diclofenac—PTGS2—Disease—HLA-A—Graves' disease	1.32e-05	0.000346	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CD4—Graves' disease	1.27e-05	0.000332	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.19e-05	0.000312	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CD4—Graves' disease	8.51e-06	0.000223	CbGpPWpGaD
